Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples
Hatim Husain, Dean C. Pavlick, Bernard J. Fendler, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, et al.
Cancer Discovery (2023) Vol. 13, Iss. 7, pp. 1572-1591
Open Access | Times Cited: 63
Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling
Stefan Alig, Mohammad Shahrokh Esfahani, Andrea Garofalo, et al.
Nature (2023) Vol. 625, Iss. 7996, pp. 778-787
Open Access | Times Cited: 41
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance
Raffaella Casolino, Philip Beer, Debyani Chakravarty, et al.
CA A Cancer Journal for Clinicians (2024) Vol. 74, Iss. 3, pp. 264-285
Open Access | Times Cited: 15
Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Christian Rolfo, Russell W. Madison, Lincoln W. Pasquina, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 11, pp. 2452-2460
Open Access | Times Cited: 13
Use of ctDNA in early breast cancer: analytical validity and clinical potential
François Panet, Andri Papakonstantinou, María Borrell, et al.
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 12
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat, Fara Brasó‐Maristany, Olga Martínez‐Sáez, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 10
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
Alessandro Russo, Jessica Lee, Lincoln W. Pasquina, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 8
Assay Validation of Cell-Free DNA Shallow Whole-Genome Sequencing to Determine Tumor Fraction in Advanced Cancers
Micah Rickles-Young, Gabriel Tinoco, Junko Tsuji, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 5, pp. 413-422
Open Access | Times Cited: 8
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors
Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery (2024) Vol. 14, Iss. 8, pp. 1440-1456
Open Access | Times Cited: 8
Liquid Biopsy and Challenge of Assay Heterogeneity for Minimal Residual Disease Assessment in Colon Cancer Treatment
Giovanni Crisafulli
Genes (2025) Vol. 16, Iss. 1, pp. 71-71
Open Access
Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling
Li‐Ting Chen, Myrthe Jager, Dàmi Rebergen, et al.
Genome Research (2025), pp. gr.279144.124-gr.279144.124
Open Access
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Pashtoon Murtaza Kasi, Jessica Lee, Lincoln W. Pasquina, et al.
Clinical Cancer Research (2023) Vol. 30, Iss. 4, pp. 836-848
Open Access | Times Cited: 19
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
Umberto Malapelle, Natasha B. Leighl, Alfredo Addeo, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 2, pp. 212-219
Open Access | Times Cited: 5
Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing
Nadine Tung, Kali Chatham Dougherty, Emily Stern Gatof, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Katherine E. Hutchinson, Jessica W. Chen, Heidi Savage, et al.
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers
Jianjiang Xie, Weishen Yao, Lingxiu Chen, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
Jianhua Zhao, Jacquelyn Reuther, Kaylee Scozzaro, et al.
Molecular Diagnosis & Therapy (2023) Vol. 27, Iss. 6, pp. 753-768
Open Access | Times Cited: 11
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, et al.
Cancer Treatment Reviews (2023) Vol. 122, pp. 102649-102649
Open Access | Times Cited: 11
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
Solange Peters, Shirish M. Gadgeel, Tony Mok, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 1923-1932
Open Access | Times Cited: 3
Hypermethylated SHOX2 in circulating cell-free DNA post renal cell carcinoma surgery as TNM-independent biomarker for recurrence risk
Thomas Büttner
American Journal of Translational Research (2024) Vol. 16, Iss. 1, pp. 304-313
Open Access | Times Cited: 3
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
Marco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Yoonha Choi, Neekesh V. Dharia, Tomi Jun, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3788-3797
Open Access | Times Cited: 3
Unique Spectrum of ActivatingBRAFAlterations in Prostate Cancer
Alex Chehrazi‐Raffle, Hanna Tukachinsky, Eamon Toye, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 19, pp. 3948-3957
Open Access | Times Cited: 9
Matched tissue and liquid biopsies for advanced non-small cell lung cancer patients A potentially indispensable complementary approach
Paul Hofman
Translational Oncology (2023) Vol. 35, pp. 101735-101735
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top